Current Report · Items 8.01, 9.01 · 8-K

Translational Development Acquisition Corp.

TDACNASDAQEQUITYCurrent

Other Events

Filed Feb 14, 2025Accepted Feb 14, 2025, 11:12 AM ESTCIK 1926599Accession 0001104659-25-014086

Company context

The Company is a blank check company incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company may pursue an acquisition opportunity in any business, industry, sector, or geographical location, and intends to focus on industries that complement its management team's background, and intends to capitalize on the ability of its management team to identify and acquire a business.

Current securities

TDACNASDAQ · EQUITY · Current TDACUNASDAQ · UNIT · Current TDACWNASDAQ · WARRANT · Current

Historical securities (1)

TDACUNASDAQ · UNIT · Historical · closed Jan 27, 2026

Recent company filings

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events

Item 8.01. Other Events. As previously reported on December 25, 2024, Translational Development Acquisition Corp. (the “Company”) consummated its initial public offering of 17,250,000 units (the “Units”), which included 2,250,000 Units issued pursuant to the exercise in full of the underwriters’ over-allotment option. Each Unit consists of one Class A ordinary share (“Ordinary Share”) and one warrant (“Warrant”). Each Warrant entitles its holder to purchase one Ordinary Share at a price of $11.50 per share (subject to adjustment). The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $172,500,000. On February 14, 2025, the Company issued a press release, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K, announcing that separate trading of Ordinary Shares and Warrants comprising the Units has commenced.

Filed exhibits (1)

EX-99.1 (by filename) tm256739d1_ex99-1.htm

EX-99.1 2 tm256739d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Translational Development Acquisition Corp. Announces that the Separate Trading of its Class A Ordinary Shares and Warrants has Commenced NEW YORK, February 14, 2025 (PRNewswire) - Translational Development Acquisition Corp. (NASDAQ: TDACU) (the “Company”) announced today that the separate trading has commenced for its Class A ordinary shares and warrants that were included in units sold in the Company’s initial public offering completed on December 24, 2024. Such Class A ordinary shares and warrants separately trade on The Nasdaq Global Market (“Nasdaq”) under the symbols “TDAC” and “TDACW,” respectively. Those units that are not separated will continue to trade on Nasdaq under the symbol “TDACU.” A registration statement relating to these securities has been declared effective by the U.S. Securities and Exchange Commission (the “SEC”). This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registratio…

Open exhibit ↗

Get the free weekly BCS email.